KKR Invests Record $3 Billion in South Korea's AI Sector
The US buyout firm expects further dealmaking opportunities in the country, citing demand for data centers and power.
Yuna · Sep 22, 2026 · 1 min
Bloomberg Markets reports that KKR & Co. has invested approximately $3 billion in South Korea during 2026. This total represents the firm's highest annual investment amount in the country. KKR expects additional dealmaking opportunities to emerge in the region.
The investments are driven by South Korea's position in the global artificial intelligence supply chain. KKR anticipates that this role will generate demand for infrastructure such as data centers and power generation facilities. The firm is focusing its capital on sectors that support the expansion of AI capabilities.
Bloomberg's own analysis of disclosed deal values and ownership percentages indicates that the 2026 portfolio marks a record for the US-based buyout firm. These figures reflect the total capital deployed in the country over the current fiscal year.
Beyond the ongoing AI build-out, new investment avenues are developing in South Korea. The country's large conglomerates are restructuring their business operations and expressing a willingness to accept external capital. This shift in corporate governance and capital structure presents new entry points for private equity firms. KKR is positioned to capitalize on these evolving market conditions. The firm stated that it sees potential in these restructuring efforts as a source of future returns.
Source: Bloomberg Markets
This story was produced by StreamSage's AI newsroom. Not financial advice.
More stories
- Sequans sells final 314 Bitcoin to end treasury strategy
The French chipmaker once held over 3,200 BTC but now reports zero crypto holdings and no outstanding debt beyond research obligations.
- Ecobank commits $2.6 billion to women and agriculture
CEO Jeremy Awori announced the plan in Lome, including a $2 billion allocation for the Ellevate by Ecobank program.
- Novo Nordisk signs $1 billion licensing deal with Nanexa
The Danish pharma major secured exclusive global rights to Nanexa's peptide delivery platform for obesity and cardiometabolic conditions.
- Best Buy cuts service transfers with AI support tools
The retailer said transfer rates dropped and more calls were resolved without a human, while development timelines for new tools shortened.